254 related articles for article (PubMed ID: 29222829)
1. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
2. Pembrolizumab-induced lichen planus pemphigoides in a patient with metastatic melanoma.
Schmidgen MI; Butsch F; Schadmand-Fischer S; Steinbrink K; Grabbe S; Weidenthaler-Barth B; Loquai C
J Dtsch Dermatol Ges; 2017 Jul; 15(7):742-745. PubMed ID: 28622432
[No Abstract] [Full Text] [Related]
3. Squamous cell carcinoma associated with chronic graft versus host disease-like/lichen planus-like lesion of the oral cavity in a patient managed for metastatic melanoma with a PD-1 inhibitor pembrolizumab.
Owosho AA; Randazzo J; Rosen EB; Estilo CL; Huryn JM; Chi P; Yom SK
Oral Oncol; 2016 Dec; 63():e1-e3. PubMed ID: 27743938
[No Abstract] [Full Text] [Related]
4. Annular atrophic lichen planus induced by anti-HER2 antibodies.
Chawla S; Turner N; Terlizzo M; Heelan K
Australas J Dermatol; 2021 May; 62(2):210-212. PubMed ID: 33216943
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab-induced pseudoepitheliomatous eruption consistent with hypertrophic lichen planus.
Coscarart A; Martel J; Lee MP; Wang AR
J Cutan Pathol; 2020 Mar; 47(3):275-279. PubMed ID: 31589773
[TBL] [Abstract][Full Text] [Related]
6. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma.
Garcia-Melendo C; Morales-Munera CE; Dalmau J; Cubiró X; López-Sánchez C; Mozos A; Yélamos O
Dermatol Ther; 2022 May; 35(5):e15388. PubMed ID: 35174945
[No Abstract] [Full Text] [Related]
7. Pembrolizumab-induced Sarcoid-like Reactions during Treatment of Metastatic Melanoma.
Cheshire SC; Board RE; Lewis AR; Gudur LD; Dobson MJ
Radiology; 2018 Nov; 289(2):564-567. PubMed ID: 30106351
[TBL] [Abstract][Full Text] [Related]
8. Lichen planus pemphigoides with antibodies against the BP180 C-terminal domain induced by pembrolizumab in a melanoma patient.
Yoshida S; Shiraishi K; Yatsuzuka K; Mori H; Koga H; Ishii N; Sayama K
J Dermatol; 2021 Sep; 48(9):e449-e451. PubMed ID: 34089265
[No Abstract] [Full Text] [Related]
9. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
10. Nivolumab PD-1 inhibitor immunotherapy associated with vulvar, perineal and perianal lichen sclerosus.
Wernham AGH; Shah F; Velangi S
Clin Exp Dermatol; 2019 Mar; 44(2):e22-e23. PubMed ID: 30430637
[No Abstract] [Full Text] [Related]
11. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
12. Delayed skin toxicity associated with pembrolizumab therapy for metastatic melanoma.
Arianayagam S; Ieremia E; Matin RN
Eur J Dermatol; 2019 Jun; 29(3):349-351. PubMed ID: 31389799
[No Abstract] [Full Text] [Related]
13. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
14. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
15. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Nardin C; Pelletier F; Puzenat E; Aubin F
Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
[No Abstract] [Full Text] [Related]
16. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
Rao BB; Robertson S; Philpott J
Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
[No Abstract] [Full Text] [Related]
17. [Linear lichen planus].
González Fernández D; Vivanco Allende B; Gómez Díez S; Pérez Oliva N
Med Clin (Barc); 2014 Apr; 142(8):e15. PubMed ID: 24210976
[No Abstract] [Full Text] [Related]
18. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
19. Rituximab in the treatment of pembrolizumab-induced myasthenia gravis.
Crusz SM; Radunovic A; Shepherd S; Shah S; Newey V; Phillips M; Lim L; Powles T; Szlosarek PW; Shamash J; Rashid S
Eur J Cancer; 2018 Oct; 102():49-51. PubMed ID: 30138772
[No Abstract] [Full Text] [Related]
20. Acrosyringeal lichen planus of palm.
Gutte RM
Indian J Dermatol Venereol Leprol; 2012; 78(4):521. PubMed ID: 22772646
[No Abstract] [Full Text] [Related]
[Next] [New Search]
